At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 183 enrolled
Drug / intervention
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion
In Brief
A Phase 3 clinical trial evaluating Macular Laser Photocoagulation and Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) for Branch Retinal Vein Occlusion. Completed, enrolled 183 participants across 56 sites in 3 countries.
Detailed Summary
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in patients with macular edema secondary to BRVO.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBranch Retinal Vein Occlusion
CountriesCanada, Japan, United States
CollaboratorsBayer
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartApr 2012
Primary CompletionAug 2013
Study CompletionMar 2014
TodayJul 2026
First PostedJan 30, 2012
Enrollment StartApr 1, 2012
Primary CompletionAug 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.4 years ago
Interventions
Macular Laser Photocoagulationprocedure
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)drug